Inflammation in peripheral artery disease

Circulation

Volumn 122, Issue 18, 2010, Pages 1862-1875

  Brevetti, Gregorio ^a   Giugliano, Giuseppe ^a   Brevetti, Linda ^a   Hiatt, William R ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; claudication; inflammation; microcirculation; peripheral vascular disease; risk factors; vessels

Indexed keywords

ANGIOTENSIN II; C REACTIVE PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY BIFURCATION; CAROTID ARTERY DISEASE; CAROTID ATHEROSCLEROSIS; CIGARETTE SMOKING; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; EXERCISE; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INTERMITTENT CLAUDICATION; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION; REVIEW; SKELETAL MUSCLE;

CAROTID ARTERY DISEASES; COMORBIDITY; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; STROKE;

EID: 78349290032     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.918417     Document Type: Review

References (210)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47: 1239-1312.
2. Bouley JF. Claudication intermittente des membres posterieurs determinee par l' obliteration des arteres femorales. Rec Med Vet. 1831;8:517.
3. Brodie BC. Lectures illustrative of various subjects in pathology and surgery. London, A Spottiswoode. 1846.
4. Charcot JMC. Sur la claudication intermittente observe dans un cas d'obliteration complete de l' une des arteres iliaques primitives. CR Soc Biol (Paris). 1858;5:225.
5. Stammers FA. Peripheral arterial disease; some points of common interest to general and orthopaedic surgery. J Bone Joint Surg Br. 1954;36-B:209-217.
6. Allen EV, Barker NW, Hines EA. Peripheral VascularDiseases. 1st ed. Philadelphia, Pa: W.B. Saunders, Co; 1946;343-401.
7. O'Riordain DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg. 1991;78:861-863.
8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
9. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, Ruckley CV. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172-1181.
10. Brevetti G, Martone VD, Perna S, Cacciatore F, Corrado S, Di Donato A, Di Iorio A. Intermittent claudication and risk of cardiovascular events. Angiology. 1998;49:843-848.
11. Brevetti G, Schiano V, Verdoliva S, Silvestro A, Sirico G, De Maio J, Lanero S, Chiariello M. Peripheral arterial disease and cardiovascular risk in Italy: results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown). 2006;7: 608-613.
12. Vance DE, Van den Bosch H. Cholesterol in the year 2000. Biochim Biophys Acta. 2000;1529:1-8.
13. Hodgson JA. Treatise on the Diseases of Arteries and Veins. London, UK: Thomas Underwood; 1815.
14. Virchow R. Cellular Pathology. London, UK: John Churchill; 1858.
15. Osler W. Diseases of the arteries. Modern Medicine: Its Practice and Theory. Philadelphia, Pa: Lea and Febiger; 1908;429-447.
16. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
17. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
18. Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis. 2008;197:1-11.
19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing pe-ripheral vascular disease. Circulation. 1998;97:425-428.
20. Bloemenkamp DG, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. Novel risk factors for peripheral arterial disease in young women. Am J Med. 2002;113:462-467.
21. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002; 106:820-825.
22. Brevetti G, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis. 2004;175:131-138.
23. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the National Health and Nutrition Examination Survey, 1999-2002. Am J Cardiol. 2005;96: 1579-1583.
24. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general pop-ulation: EdinburghArtery Study. Circulation. 2005;112:976-983.
25. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM. Plasma MCP-1 level and risk for periph-eral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005;183:301-307.
26. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005;29:171-176.
27. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident periph-eral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28: 354-362.
28. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, Ruckley CV. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331-340.
29. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96:44-49.
30. Pryor WA, Stone K. Oxidants in cigarette smoke: radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N YAcad Sci. 1993;686: 12-27.
31. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ. Increase in circulating products of lipid perioxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;76:1198-1203.
32. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic compli-cations: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
33. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219-242.
34. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
35. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension. 1997; 29:366-373.
36. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-1629.
37. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of earlyacceleratedatherosclerosis. Circulation. 1997;95:1532-1541.
38. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100:1223-1229.
39. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:5134-5138.
40. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 1990;344:254-257.
41. Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW, Knottnerus JA. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease: the Limburg PAOD Study: Peripheral Arterial Occlusive Disease. Scand J Prim Health Care. 1998;16:177-182.
42. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004;62:499-506.
43. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292-2301.
44. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and reg-ulatory pathways. Physiol Rev. 2006;86:515-581.
45. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89:601-609.
46. Braunersreuther V, Mach F, Steffens S. The specific role ofchemokines in atherosclerosis. Thromb Haemost. 2007;97:714-721.
47. Roldan V, Marin F, Lip GY, Blann AD. Soluble E-selectin in cardio-vascular disease and its risk factors: a review of the literature. Thromb Haemost. 2003;90:1007-1020.
48. Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degra-dation and efflux. Atherosclerosis. 1999;143:229-243.
49. Carmelli D, Fabsitz RR, Swan GE, Reed T, Miller B, Wolf PA. Con-tribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study: National Heart, Lung, and Blood Institute. Am J Epidemiol. 2000;151:452-458.
50. Murabito JM, Guo CY, Fox CS, D'Agostino RB. Heritability of the ankle-brachial index: the Framingham Offspring Study. Am J Epidemiol. 2006;164:963-968.
51. Kullo IJ, Turner ST, Kardia SL, Mosley TH Jr, Boerwinkle E, de AM. A genome-wide linkage scan for ankle-brachial index in African American and non-Hispanic white subjects participating in the GENOA study. Atherosclerosis. 2006;187:433-438.
52. Gaetani E, Flex A, Pola R, Papaleo P, De Martini D, Pola E, Aloi F, Flore R, Serricchio M, Gasbarrini A, Pola P. The K469E polymorphism of the ICAM-1 gene is a risk factor for peripheral arterial occlusive disease. Blood Coagul Fibrinolysis. 2002;13:483-488.
53. Flex A, Gaetani E, Angelini F, Sabusco A, Chilla C, Straface G, Biscetti F, Pola P, Castellot JJ Jr, Pola R. Proinflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med. 2007;262:124-130.
54. Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Ossewaarde JM, Visseren FL, van Loon AM, van der Graaf Y. Chlamydiapneumoniae, Helicobacterpylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis. 2002;163:149-156.
55. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG, Perrea D, Kostakis AG. Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2006;31:509-515.
56. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Hel-icobacterpylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102: 833-839.
57. Ridker PM. Are associations between infection and coronary disease causal or due to confounding? Am J Med. 1999;106:376-377.
58. Mendez MV, Scott T, LaMorte W, Vokonas P, Menzoian JO, Garcia R. An association between periodontal disease and peripheral vascular disease. Am J Surg. 1998;176:153-157.
59. Hung HC, Willett W, Merchant A, Rosner BA, Ascherio A, Joshipura KJ. Oral health and peripheral arterial disease. Circulation. 2003;107: 1152-1157.
60. Wiesli P, Schulthess G. Effect of roxithromycin treatment on the endo-thelial function of Chlamydia pneumoniae seropositive men suffering from peripheral arterial occlusive disease. Circulation. 2002;106:e226.
61. Wiesli P, Czerwenka W, Meniconi A, Maly FE, Hoffmann U, Vetter W, Schulthess G. Roxithromycin treatment prevents progression of periph-eral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646-2652.
62. Krayenbuehl PA, Wiesli P, Maly FE, Vetter W, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis. 2005;179:103-110.
63. Joensen JB, Juul S, Henneberg E, Thomsen G, Ostergaard L, Lindholt JS. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis. 2008;196:937-942.
64. Jaff MR, Dale RA, Creager MA, Lipicky RJ, Constant J, Campbell LA, Hiatt WR. Antichlamydial antibiotic therapy for symptom improvement in peripheral artery disease: Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia pneumoniae Seropositive Patients (PROVIDENCE-1). Circulation. 2009;119:452-458.
65. Liang KP, Liang KV, Matteson EL, McClelland RL, Christianson TJ, Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum. 2006;54:642-648.
66. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford). 2003;42:292-297.
67. McDonald J, Stewart J, Urowitz MB, Gladman DD. Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51:56-60.
68. Theodoridou A, Bento L, D'Cruz DP, Khamashta MA, Hughes GR. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis. 2003;62: 1199-1203.
69. Henke PK, Sukheepod P, Proctor MC, Upchurch GR Jr, Stanley JC. Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus. J Vasc Surg. 2003;38:111-115.
70. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000;59:321-325.
71. Sabouret P, Cacoub P, Dallongeville J, Krempf M, Mas JL, Pinel JF, Priollet P, Steg G, Taminau D, Montalescot G. REACH: international prospective observational registry in patients at risk of atherothrombotic events: results for the French arm at baseline and one year. Arch Cardiovasc Dis. 2008;101:81-88.
72. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
73. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, Stoll G. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29: 1625-1630.
74. Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sorensen K, Russell D, Dahl A, Ueland T, Oie E, Aukrust P, Halvorsen B. Soluble CD36 in plasma is increased in patients with symptomatic athero-sclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39:3092-3095.
75. Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. Creactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch Surg. 2007;142:1066-1071.
76. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis: NorthAmerican Symptomatic Carotid End-arterectomy Trial Collaborators. N Engl J Med. 1991;325:445-453.
77. Gronholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E, Sillesen H. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg. 2002;35:137-145.
78. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, Timmel E, Kickinger B, Minar C, Pones M, Lalouschek W, Rumpold H, Maurer G, Wagner O, Minar E. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation. 2005; 111:2203-2209.
79. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, Kuller LH, Cushman M. Association of carotid artery intima-media thickness, plaques, and Creactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32-38.
80. Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K, Kondo K, Masuyama T, Matsumoto M, Hori M. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004;35:677-681.
81. Alvarez GB, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity Creactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003;38:1018-1024.
82. Langsfeld M, Gray-Weale AC, Lusby RJ. The role of plaque mor-phology and diameter reduction in the development of new symptoms in asymptomatic carotid arteries. J Vasc Surg. 1989;9:548-557.
83. Barnett HJ, Gunton RW, Eliasziw M, Fleming L, Sharpe B, Gates P, Meldrum H. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA. 2000;283:1429-1436.
84. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002;15: 439-446.
85. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
86. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69: 377-381.
87. Fuster V. Lewis A. Conner Memorial Lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
88. Davies MJ, Thomas AC Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
89. Richardson PD, Davies MJ, Born GV. Influence ofplaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
90. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
91. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
92. Tauth J, Pinnow E, Sullebarger JT, Basta L, Gursoy S, Lindsay J Jr, Matar F. Predictors of coronary arterial remodeling patterns in patients with myocardial ischemia. Am J Cardiol. 1997;80:1352-1355.
93. Gronholdt ML, Nordestgaard BG, Wiebe BM, Wilhjelm JE, Sillesen H. Echolucency of computerized ultrasound images of carotid athero-sclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation. 1998; 97:34-40.
94. Lal BK, Hobson RW, Pappas PJ, Kubicka R, Hameed M, Chakhtoura EY, Jamil Z, Padberg FT Jr, Haser PB, Duran WN. Pixel distribution analysis of B-mode ultrasound scan images predicts histologic features of atherosclerotic carotid plaques. J Vasc Surg. 2002;35:1210-1217.
95. McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, Ferrucci L. Patterns of inflammation associated with peripheral arte-rial disease: the InCHIANTI study. Am Heart J. 2005;150:276-281.
96. Brevetti G, Martone VD, de Cristofaro T, Corrado S, Silvestro A, Di Donato AM, Bucur R, Scopacasa F. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost. 2001;85: 63-66.
97. Silvestro A, Scopacasa F, Ruocco A, Oliva G, Schiano V, Zincarelli C, Brevetti G. Inflammatory status and endothelial function in asymptom-atic and symptomatic peripheral arterial disease. Vasc Med. 2003;8: 225-232.
98. Sirico G, Brevetti G, Lanero S, Laurenzano E, Luciano R, Chiariello M. Echolucent femoral plaques entail higher risk of echolucent carotid plaques and a more severe inflammatory profile in peripheral arterial disease. J Vasc Surg. 2009;49:346-351.
99. Gronholdt ML, Sillesen H, Wiebe BM, Laursen H, Nordestgaard BG. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg. 2001; 21:227-234.
100. Rossi A, Franceschini L, Fusaro M, Cicoira M, Eleas AA, Golia G, Bonapace S, Santini F, Sangiorgi G, Zardini P, Vassanelli C. Carotid atherosclerotic plaque instability in patients with acute myocardial infarction. Int J Cardiol. 2006;111:263-266.
101. Lombardo A, Biasucci LM, Lanza GA, Coli S, Silvestri P, Cianflone D, Liuzzo G, Burzotta F, Crea F, Maseri A. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004;109: 3158-3163.
102. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, Graor RA, Dewolfe VG, Maljovec LC. Coronary artery disease in peripheral vascular patients: a classification of 1000 coronary angiograms and results of surgical management Ann Surg. 1984;199:223-233.
103. Valentine R, Grayburn PA, Eichhorn EJ, Myers S, Clagett GP. Coronary artery disease is highly prevalent among patients with premature periph-eral vascular disease. J Vasc Surg. 1994;19:688-674.
104. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384-392.
105. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: mor-bidity and mortality implications. Circulation. 2006;114:688-699.
106. Brevetti G, Piscione F, Silvestro A, Galasso G, Di Donato A, Oliva G, Scopacasa F, Chiariello M. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with con-comitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003;89:1058-1063.
107. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999;19: 2355-2363.
108. Burek KA, Sutton-Tyrrell K, Brooks MM, Naydeck B, Keller N, Sellers MA, Roubin G, Jandova R, Rihal CS. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revasculariza-tion in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. 1999;34:716-721.
109. Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Char-lesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syn-dromes: are we doing enough? Results from the Orbofiban in Patients With Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003;145:622-627.
110. Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, Budaj A, Avezum A, Allegrone J, FitzGerald G, Steg PG. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007; 100:1-6.
111. Karnegis JN, Matts JP, Tuna N, Hunter D, Amplatz K. Correlation of coronary with peripheral arterial stenosis: the POSCH Group. Atherosclerosis. 1992;92:25-30.
112. Menotti A, Lanti M, Puddu PE. Twenty-five-year cardiovascular disease incidence among middle-aged men: disease burden, time shape, pre-dictors, risk probabilities. Ital Heart J. 2000;1:749-757.
113. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209-215.
114. Vink A, Schoneveld AH, Richard W, de Kleijn DP, Falk E, Borst C, Pasterkamp G. Plaque burden, arterial remodeling and plaque vulnera-bility: determined by systemic factors? J Am Coll Cardiol. 2001;38: 718-723.
115. Pasterkamp G, Schoneveld AH, van der Wal AC, Hijnen DJ, van Wolveren WJ, Plomp S, Teepen HL, Borst C. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol. 1999;19:54-58.
116. Brevetti G, Piscione F, Cirillo P, Galasso G, Schiano V, Barbato E, Scopacasa F, Chiariello M. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis. 2008;201:440-446.
117. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102-1111.
118. Edwards AT, Blann AD, Suarez-Mendez VJ, Lardi AM, McCollum CN. Systemic responses in patients with intermittent claudication after treadmillexercise. Br J Surg. 1994;81:1738-1741.
119. Belch JJ, McLaren M, Khan F, Hickman P, Muir AH, Stonebridge PA. The inflammatory process in intermittent claudication. Eur Heart J. 2002;4:B31-B34.
120. Silvestro A, Scopacasa F, Oliva G, de Cristofaro T, Iuliano L, Brevetti G. Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis. 2002;165:277-283.
121. Kirk G, Hickman P, McLaren M, Stonebridge PA, Belch JJ. Inter-leukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg. 1999;18:434-438.
122. Brevetti G, Corrado S, Martone VD, Di Donato A, Silvestro A, Vanni L. Microcirculation and tissue metabolism in peripheral arterial disease. Clin Hemorheol Microcirc. 1999;21:245-254.
123. Papamichael CM, Lekakis JP, Stamatelopoulos KS, Papaioannou TG, Alevizaki MK, Cimponeriu AT, Kanakakis JE, Papapanagiotou A, Kalofoutis AT, Stamatelopoulos SF. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2000;86:615-618.
124. Tataru MC, Heinrich J, Junker R, Schulte H, von EA, Assmann G, Koehler E. Creactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21:1000-1008.
125. Makowsky MJ, McAlister FA, Galbraith PD, Southern DA, Ghali WA, Knudtson ML, Tsuyuki RT. Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Am Heart J. 2008;155:348-355.
126. Brevetti G, Piscione F, Schiano V, Galasso G, Scopacasa F, Chiariello M. Concomitant coronary and peripheral arterial disease: relationship between the inflammatory status of the affected limb and the severity of coronary artery disease. J Vasc Surg. 2009;49:1465-1471.
127. Brevetti G, Sirico G, Giugliano G, Lanero S, De Maio JI, Luciano R, Laurenzano E, Chiariello M. Prevalence of hypoechoic carotid plaques in coronary artery disease: relationship with coexistent peripheral arte-rial disease and leukocyte number. Vasc Med. 2009;14:13-19.
128. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E. Relationship between intermittent claudication, inflam-mation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med. 2004;164:440-446.
129. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, Bax JJ, van Sambeek MR, Poldermans D. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51: 1588-1596.
130. MRC/BHF Heart Protection Study of cholesterol lowering with simva-statin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
131. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of periph-eral vascular disease: the Coronary Artery Surgery Study (CASS) Inves-tigators. J Am Coll Cardiol. 1994;23:1091-1095.
132. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Anklearm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study: the Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
133. Vogt MT, McKenna M, Wolfson SK, Kuller LH. The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women. Atherosclerosis. 1993; 101:191-202.
134. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between Anklearm index and mortality in older men and women. J Am GeriatrSoc. 1993;41:523-530.
135. Pasqualini L, Schillaci G, Vaudo G, Innocente S, Ciuffetti G, Mannarino E. Predictors of overall and cardiovascular mortality in peripheral arte-rial disease. Am J Cardiol. 2001;88:1057-1060.
136. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C, Ginnetti F, Angiolillo DJ, Grieco G, Liuzzo G, Maseri A. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of Creactive protein. Circulation. 2002;105:800-803.
137. Vainas T, Stassen FR, de GR, Twiss EL, Herngreen SB, Welten RJ, van den Akker LH, van Dieijen-Visser MP, Bruggeman CA, Kitslaar PJ. Creactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42: 243-251.
138. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005;96: 1374-1378.
139. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, Greenland P, Green D, Tan J, Garside DB, Guralnik J, Ridker PM, Rifai N, McDermott MM. Biomarkers of inflammation and thrombosis as pre-dictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008;148:85-93.
140. Schlager O, Amighi J, Haumer M, Sabeti S, Dick P, Mlekusch W, Loewe C, Koppensteiner R, Minar E, Schillinger M. Inflammation and adverse cardiovascular outcome in patients with renal artery stenosis and peripheral artery disease. Atherosclerosis. 2009;205:314-318.
141. Hogh AL, Joensen J, Lindholt JS, Jacobsen MR, Ostergaard L. Creactive protein predicts future arterial and cardiovascular events in patients with symptomatic peripheral arterial disease. Vasc Endovascular Surg. 2008;42: 341-347.
142. Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Sco-pacasa F, Chiariello M. Myeloperoxidase, but not Creactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J. 2008;29:224-230.
143. Blann AD, Seigneur M, Steiner M, Miller JP, McCollum CN. Circu-lating ICAM-1 and VCAM-1 in peripheral artery disease and hypercho-lesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost. 1998;79:1080-1085.
144. Silvestro A, Brevetti G, Schiano V, Scopacasa F, Chiariello M. Adhesion molecules and cardiovascular risk in peripheral arterial disease: soluble vascular cell adhesion molecule-1 improves risk strat-ification. Thromb Haemost. 2005;93:559-563.
145. Dormandy JA, Murray GD. The fate of the claudicant: a prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5:131-133.
146. Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease: results from the A.D.E.P. study. Atherosclerosis. 1996; 120:25-35.
147. Haumer M, Amighi J, Exner M, Mlekusch W, Sabeti S, Schlager O, Schwarzinger I, Wagner O, Minar E, Schillinger M. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg. 2005;41:610-617.
148. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Asso-ciation. Circulation. 2003;107:499-511.
149. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. Creactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
150. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108: 1440-1445.
151. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR. An assessment of incremental coronary risk prediction using Creactive protein and other novel risk markers: the Atherosclerosis Risk in Com-munities study. Arch Intern Med. 2006;166:1368-1373.
152. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, Creactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609-1616.
153. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardio-vascular events and death. N Engl J Med. 2006;355:2631-2639.
154. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor ofmyocardial infarction. N Engl J Med. 1974;290:1275-1278.
155. Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, Windham GB, Ble A, Senin U, Ferrucci L. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2007;49:1841-1850.
156. Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. Am J Cardiol. 2001;88:1221-1224.
157. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638-1643.
158. Giugliano G, Brevetti G, Lanero S, Schiano V, Laurenzano E, Chiariello M. Leukocyte count in peripheral arterial disease: a simple, reliable, inexpensive approach to cardiovascular risk prediction. Atherosclerosis. 2010;210:288-293.
159. Erb W. Uber das "intermittiende Hinken" und andere nervose Storungen in Folde von Gefaberkrankungen. Deutsch Zeitschrift fur Nervenheilkunde. 1898;13:1-76.
160. Comroe JH. Paroxysmal angiospasm dolorosa. Ann Clin Med. 1922;1: 313-316.
161. Leary WV, Allen EV. Intermittent claudication as a result of arterial spasm induced by walking. Am Heart J. 1941;22:719-724.
162. Lindquist T. Intermittent claudication and vascular spasm, I: is vascular spasm a contributing cause of intermittent claudication in patients with structural disease of the arteries? Acta Med Scand. 1945;121:32-44.
163. Ejrup B. Tonoscillography after exercise. Acta Med Scand Suppl. 1948; 211:1-7.
164. Lewis T, Pichering G, Rotschild P. Observations upon muscular pain in intermittentclaudication. Heart. 1931;15:359-366.
165. Skinner JS, Strandness DE. Exercise and intermittent claudication, I: effect of repetition and intensity of exercise. Circulation. 1967;36: 15-22.
166. Winsor T, Hyman C, Payne JH. Exercise and limb circulation in health and disease. AMA Arch Surg. 1959;78:184-192.
167. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. Vasc Med. 2000;5:55-59.
168. Brass EP, Hiatt WR, Green S. Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpointdiscussion. Vasc Med. 2004;9:293-301.
169. 2 dynamics during treadmill and arm exercise in peripheral arterial disease. J Appl Physiol. 2004;97:627-634.
170. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. BMJ. 1973;4:576-581.
171. Reid HL, Dormandy JA, Barnes AJ, Lock PJ, Dormandy TL. Impaired red cell deformability in peripheral vascular disease. Lancet. 1976;1: 666-668.
172. Belch JJ, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol. 1995;14:385-388.
173. Brevetti G, De Catarina M, Martone VD, Ungaro B, Corrado F, Silvestro A, de Cristofaro T, Scopacasa F. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudi-cation. Clin Hemorheol Microcirc. 2001;24:193-199.
174. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G, Marchese G, Costa MP, Digrandi D, Celotta G, Virgilio V. High circulating levels ofcytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 2003;8:15-19.
175. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74: 626-630.
176. Mangiafico RA, Malatino LS, Spada RS, Santonocito M, Messina R, Dell'Arte S, Attina T. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb. Int Angiol. 2000;19:14-17.
177. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374-379.
178. Neumann FJ, Waas W, Diehm C, Weiss T, Haupt HM, Zimmermann R, Tillmanns H, Kubler W. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation. 1990;82: 922-929.
179. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation: essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem. 1999;274:29108-29114.
180. Kirkpatrick UJ, Mossa M, Blann AD, McCollum CN. Repeated exercise induces release of soluble P-selectin in patients with intermittent clau-dication. ThrombHaemost. 1997;78:1338-1342.
181. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. 2003;38:99-103.
182. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease, part I: their expression and role in atherogenesis. Intern Med J. 2003;33:380-386.
183. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, Wallin R. Neutrophil function in ischemic heart disease. Circulation. 1989;79:549-556.
184. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leu-kocytes in peripheral arterial disease and the normal population in the EdinburghArteryStudy. Circulation. 1993;87:1915-1920.
185. Turton EP, Coughlin PA, Kester RC, Scott DJ. Exercise training reduces the acute inflammatory response associated with claudication. Eur J Vasc Endovasc Surg. 2002;23:309-316.
186. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR. Chronic changes in skeletal muscle his-tology and function in peripheral arterial disease. Circulation. 1993;87: 413-421.
187. Askew CD, Green S, Walker PJ, Kerr GK, Green AA, Williams AD, Febbraio MA. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vasc Surg. 2005; 41:802-807.
188. McGuigan MR, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, Kraemer WJ. Muscle fiber characteristics in patients with periph-eral arterial disease. Med Sci Sports Exerc. 2001;33:2016-2021.
189. Mitchell RG, Duscha BD, Robbins JL, Redfern SI, Chung J, Bensimhon DR, Kraus WE, HiattWR, Regensteiner JG, Annex BH. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med. 2007;12:285-290.
190. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mito-chondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation. 1999;99:807-812.
191. Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol. 1991;260:E727-E730.
192. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med. 1994;205:182-185.
193. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci MedSci. 2002;57:M326-M332.
194. Meadows KA, Holly JM, Stewart CE. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol. 2000;183:330-337.
195. McDermott MM, Ferrucci L, Guralnik JM, Tian L, Green D, Liu K, Tan J, Liao Y, Pearce WH, Schneider JR, Ridker P, Rifai N, Hoff F, Criqui MH. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol. 2007;50: 897-905.
196. Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri CG, Fallico R, Di Pino L, Pennisi G, Celotta G, Massimiliano A. A ran-domised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemo-dialysis. DrugsAging. 2006;23:263-270.
197. Andreozzi GM, Martini R, Cordova R, D'Eri A, Salmistraro G, Mussap M, Plebani M. Circulating levels of cytokines (IL-6 and IL-1beta) in patients with intermittent claudication, at rest, after maximal exercise treadmill test and during restore phase: could they be progression markers of the disease? Int Angiol. 2007;26:245-252.
198. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Attisano T, Ambrosio G, Siliprandi N, Angelini C. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77: 767-773.
199. Kemp GJ, Hands LJ, Ramaswami G, Taylor DJ, Nicolaides A, Amato A, Radda GK. Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy. Clin Sci (Colch). 1995;89:581-590.
200. van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, Hofman A, Witteman JC. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2002;22:838-842.
201. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression ofperipheral arterial disease in large and small vessels. Circulation. 2006;113:2623-2629.
202. Musicant SE, Taylor LM Jr, Peters D, Schuff RA, Urankar R, Landry GJ, Moneta GL. Prospective evaluation of the relationship between Creactive protein, D-dimer and progression of peripheral arterial disease. J Vasc Surg. 2006;43:772-780.
203. Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med. 2006;11:21-28.
204. Majewski W, Zielinski A, Laciak M, Staniszewski R, Gorny A, Zapalski S, Mackiewicz A. Creactive protein and alpha-1-acid glycoprotein in monitoring ofpatients withchronic arterial occlusion of the lower limbs. Eur J Vasc Surg. 1993;7:628-632.
205. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation. 2003;107:3191-3198.
206. McDermott MM, Greenland P, Guralnik JM, Ferrucci L, Green D, Liu K, Criqui MH, Schneider JR, Chan C, Ridker P, Pearce WH, Martin G, Clark E, Taylor L. Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. Vasc Med. 2004;9:107-115.
207. McDermott MM, Liu K, Guralnik JM, Ferrucci L, Green D, Greenland P, Tian L, Criqui MH, Lo C, Rifai N, Ridker PM, Zheng J, Pearce W. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of Creactive protein and D-dimer. J Gerontol A Biol Sci Med Sci. 2006;61:374-379.
208. Schiano V, Brevetti G, Sirico G, Silvestro A, Giugliano G, Chiariello M. Functional status measured by walking impairment questionnaire and cardiovascular risk prediction in peripheral arterial disease: results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. Vasc Med. 2006;11:147-154.
209. McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, Pearce WH, Schneider JR, Criqui MH. Prognostic value of functional per-formance for mortality in patients with peripheral artery disease. J Am Coll Cardiol. 2008;51:1482-1489.
210. Darbar D, Gillespie N, Main G, Bridges AB, Kennedy NS, Pringle TH, McNeill GP. Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. Am J Cardiol. 1996;78:736-740.